Today, Alexion Pharmaceuticals Inc. (ALXN) Raised to Sell at Vetr Inc.

Today, Alexion Pharmaceuticals Inc. (ALXN) Raised to Sell at Vetr Inc.

Vetr upgraded shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) from a strong sell rating to a sell rating in a research note issued to investors on Wednesday. They currently have $107.00 price target on the biopharmaceutical company’s stock.

ALXN has been the topic of a number of other research reports. Jefferies Group dropped their price target on Alexion Pharmaceuticals from $140.00 to $120.00 and set a hold rating on the stock in a research note on Friday, September 23rd. Leerink Swann increased their price objective on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the stock an outperform rating in a research report on Monday, September 26th. FBR & Co reiterated a sell rating on shares of Alexion Pharmaceuticals in a research report on Friday, October 7th. Citigroup Inc. increased their price objective on Alexion Pharmaceuticals from $154.00 to $155.00 and gave the stock a buy rating in a research report on Tuesday, September 20th. Finally, Zacks Investment Research upgraded Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 27th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $176.10.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 118.34 on Wednesday. The stock has a 50 day moving average of $125.95 and a 200 day moving average of $134.40. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45. The firm has a market cap of $26.54 billion, a P/E ratio of 297.34 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The business earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. During the same quarter last year, the company posted $1.44 EPS. The firm’s revenue was up 18.4% on a year-over-year basis. Analysts anticipate that Alexion Pharmaceuticals will post $4.67 earnings per share for the current fiscal year.

In other news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the completion of the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at $25,955,939.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vikas Sinha sold 277 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $37,987.78. Following the transaction, the chief financial officer now owns 178,463 shares of the company’s stock, valued at $24,474,415.82. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $34,314,000. Legal & General Group Plc increased its stake in shares of Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares during the last quarter. Strs Ohio increased its stake in shares of Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares during the last quarter. Gateway Investment Advisers LLC increased its stake in shares of Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Alexion Pharmaceuticals by 4.4% in the second quarter. Candriam Luxembourg S.C.A. now owns 143,411 shares of the biopharmaceutical company’s stock worth $16,745,000 after buying an additional 6,017 shares during the last quarter. Institutional investors own 96.36% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Related posts

Leave a Comment